Creative Medical Technology Holdings (CELZ) Net Margin (2017 - 2025)
Creative Medical Technology Holdings' (CELZ) quarterly Net Margin came in at 103999.83% in Q4 2025, down 477270.0% year-over-year from N/an in Q4 2024, and down 90.46% quarter-over-quarter from 54603.23% in Q1 2025.
Powered by 
Analysis
Creative Medical Technology Holdings (CELZ) Net Margin (2017 - 2025) Analysis & Trends
Creative Medical Technology Holdings (CELZ) has reported Net Margin for 9 consecutive years, with 103999.83% the latest figure, recorded in Q4 2025.
- On a quarterly basis, Net Margin fell 477270.0% year-over-year to 103999.83% in Q4 2025; TTM through Jun 2026 was 242363.2%, a 12755738.0% decrease from a year earlier, with the FY2025 full-year figure at 120455.48%, down 6030802.0% from the prior year.
- Net Margin was 103999.83% for Q4 2025 at Creative Medical Technology Holdings, down from 54603.23% in the prior quarter.
- Over five years, Net Margin peaked at 1786.07% in Q3 2022 and troughed at 103999.83% in Q4 2025.
- A 5-year average of 37799.78% and a median of 26642.18% in 2021 frame the typical range for Net Margin.
- Across the five-year window, Net Margin soared 21639876 bps in 2021 and tumbled 4327467 bps in 2024, its largest moves.
- Over 5 years, Net Margin stood at 5719.92% in 2021, then tumbled by 484 bps to 33417.7% in 2022, then sank by 67 bps to 55952.47% in 2023, then tumbled by 77 bps to 99227.13% in 2024, then declined by 5 bps to 103999.83% in 2025.
- The last three Net Margin figures came in at 103999.83% (Q4 2025), 54603.23% (Q1 2025), and 99227.13% (Q4 2024), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.60 Bn | 9.76 Bn | 112.79 Mn | 45.94% |
| 2 | CRISPR Therapeutics AG | 5.39 Bn | 5.39 Bn | - | -895.73% |
| 3 | Iovance Biotherapeutics | 3.98 Bn | 3.68 Bn | 55.72 Mn | -47.62% |
| 4 | Legend Biotech | 3.97 Bn | 3.00 Bn | 251.50 Mn | 20.08% |
| 5 | uniQure | 3.09 Bn | 3.09 Bn | 5.49 Mn | -1,387.76% |
| 6 | Beam Therapeutics | 3.06 Bn | 3.06 Bn | - | -25,036.33% |
| 7 | Precigen | 2.54 Bn | 2.54 Bn | 52.17 Mn | 36.51% |
| 8 | Sarepta Therapeutics | 2.38 Bn | 1.58 Bn | 251.87 Mn | -1.22% |
| 9 | Vericel | 2.06 Bn | 1.89 Bn | 56.40 Mn | 2.88% |
| 10 | Creative Medical Technology Holdings | 1.48 Mn | 1.50 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -103,999.83% |
| Mar 31, 2025 | -54,603.23% |
| Dec 31, 2024 | -99,227.13% |
| Jun 30, 2024 | -19,471.60% |
| Dec 31, 2023 | -55,952.47% |
| Sep 30, 2023 | -24,232.53% |
| Dec 31, 2022 | -33,417.70% |
| Sep 30, 2022 | -1,786.07% |
| Mar 31, 2022 | -7,699.13% |
| Dec 31, 2021 | -5,719.92% |
| Sep 30, 2021 | -18,435.96% |
| Jun 30, 2021 | -29,051.82% |
| Dec 31, 2020 | -222,118.68% |
| Sep 30, 2020 | 512.79% |
| Jun 30, 2020 | -6,604.17% |
| Mar 31, 2020 | 8,889.50% |
| Dec 31, 2019 | 124,198.86% |
| Sep 30, 2019 | -4,184.56% |
| Jun 30, 2019 | -143.24% |
| Mar 31, 2019 | -1,569.62% |